Last reviewed · How we verify

Somatostatin (octreotide) — Competitive Intelligence Brief

Somatostatin (octreotide) (Somatostatin (octreotide)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin analog. Area: Oncology; Endocrinology.

phase 3 Somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Somatostatin (octreotide) (Somatostatin (octreotide)) — University Hospital Freiburg. Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Somatostatin (octreotide) TARGET Somatostatin (octreotide) University Hospital Freiburg phase 3 Somatostatin analog Somatostatin receptors (SSTR2, SSTR5)
Signifor PASIREOTIDE Recordati marketed Somatostatin Analog [EPC] Somatostatin receptor type 5 2012-01-01
Somatuline Depot LANREOTIDE Ipsen Pharma marketed Somatostatin Analog Somatostatin receptor type 2 2007-01-01
Sandostatin OCTREOTIDE Novartis marketed Somatostatin Analog Somatostatin receptor type 2 1988-01-01
norepinephrine versus midodrine & octreotide norepinephrine versus midodrine & octreotide National Hepatology & Tropical Medicine Research Institute marketed Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor
LAR Lanreotide LAR Lanreotide Memorial Sloan Kettering Cancer Center marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5)
Pegvisomant/ Sandostatin LAR Pegvisomant/ Sandostatin LAR Pfizer marketed Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR) Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Somatostatin analog class)

  1. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  2. Camurus AB · 1 drug in this class
  3. Cedars-Sinai Medical Center · 1 drug in this class
  4. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
  5. Debiovision · 1 drug in this class
  6. Ipsen · 1 drug in this class
  7. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  8. Lahore General Hospital · 1 drug in this class
  9. Mario Negri Institute for Pharmacological Research · 1 drug in this class
  10. Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Somatostatin (octreotide) — Competitive Intelligence Brief. https://druglandscape.com/ci/somatostatin-octreotide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: